← All trials
NCT04344795
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 22, 2020
- Primary completion
- Aug 31, 2021
- Completion date
- Jul 31, 2022
- First posted
- Apr 14, 2020
- Last posted
- Apr 15, 2020
- Enrollment
- 60
- Arms / groups
- 4 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Tempest TherapeuticsLead sponsor
- Tempest TherapeuticsStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.